<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01260636</url>
  </required_header>
  <id_info>
    <org_study_id>MH-137</org_study_id>
    <nct_id>NCT01260636</nct_id>
  </id_info>
  <brief_title>Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries</brief_title>
  <acronym>VALUE</acronym>
  <official_title>A Phase III, Comparative Multi-center Randomized Double-blind, Crossover Study of the Safety, Tolerability and Diagnostic Efficacy of Gadobenate Dimeglumine and Gadopentetate Dimeglumine in Magnetic Resonance Angiography of the Carotid, Renal/Abdominal and Peripheral Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bracco Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bracco Diagnostics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare two gadolinium contrast agents in terms of global paired diagnostic preference
      (primary endpoint) for the assessment of contrast-enhanced MR Angiography of the carotid,
      renal/abdominal and peripheral arteries
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic Preference</measure>
    <time_frame>Immediately post dose</time_frame>
    <description>Comparison of a single dose of MultiHance versus the double dose of Magnevist currently used for MR Angiography of the carotid, renal/abdominal/ and peripheral arteries in terms of global diagnostic perference</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety comparison of two diagnostic agents</measure>
    <time_frame>UP to 24 hours post dose of each contrast agent</time_frame>
    <description>to compare the safety of the two investigational products in patients undergoing CE-MRA of the carotid, renal/abdominal and peripheral arteries</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Carotid, Aortic, Renal or Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>MultiHance contrast agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MultiHance administered at a dose of 0.1 mmol/kg (0.2 mL/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnevist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Magnevist administered at a dose of 0.2 mmol/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadobenate Dimeglumine</intervention_name>
    <description>0.1 mmol/kg, single dose</description>
    <arm_group_label>MultiHance contrast agent</arm_group_label>
    <other_name>MultiHance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadopentetate Dimeglumine</intervention_name>
    <description>Double dose of 0.2 mmol/kg</description>
    <arm_group_label>Magnevist</arm_group_label>
    <other_name>Magnevist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 yrs of age or older

          -  referred for enhanced MRA of carotid, renal/abdominal or peripheral arteries

          -  Able to provide written informed consent and comply with protocol requirements

          -  Highly suspected of or with known disease of the carotid, renal/abdominal or
             peripheral vasculature using specific criteria listed in the protocol

        Exclusion Criteria:

          -  pregnant or lactating females

          -  Known allergy to one or more of the ingredients in the products under investigation

          -  Significant congestive heart failure ( Class IV)

          -  Moderate to severe chronic kidney disease

          -  Therapeutic intervention of any kind for vascular disease in the territory of interest
             between the two contrast procedures

          -  Vascular stents in vessels of interest

          -  Received another contrast agent in the 24 hrs preceding or proceeding each exam

          -  Previously entered into the study

          -  Contraindications to MRI

          -  Severe Claustrophobia Undergone DSA between the two exams
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radiology Department Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2010</study_first_submitted>
  <study_first_submitted_qc>December 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2010</study_first_posted>
  <last_update_submitted>January 4, 2012</last_update_submitted>
  <last_update_submitted_qc>January 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

